All good observations chemist823 yet the company as of yet has failed to gain traction with the large funds. Much of it likely has to do with fact that there is a finite number of them that are even allowed to participate in stocks that trade below 5.00. Once the company gets tot the next level with stage III clinical trials that have large cohorts, I believe we are going to see the price ramp up based upon the intellectual property valuation alone. Slowly but surely this company is building a portfolio that will ultimately prove to be a gold mine for somebody (me). I keep averaging down - something I never advise but occasionally engage in. The longer we stay at these levels for my weekly purchases, the wealthier I will become during the end game. (big pharma partner or buyout).
My advice to you is to DUMP Kaiser Permanente if you have a choice. They have always practiced "industrial style" medicine and are second rate. Are these people the proper stewards of YOUR life? Anthem wants your business and has just gone out of their way to let you know it!
that failed to step up to the plate and buy shares anywhere below $10
An agreement with the likes of Anthem Blue Cross is significant and it is my opinion this is the first major endorsement that will cascade into future announcements. These guys (Anthem) have to be "about the money" and would not act otherwise. It is in THEIR best interest, as it is with all insurers to cover the low cost of diagnostics that their customers, the patients are likely to comply with as opposed to an expensive test that everyone ignores. As has been noted here on multiple occasions, it is far more expensive to treat colon cancer than to prevent it, not only in dollar terms but in terms of human life.
Wrong. This is how the daytraders take advantage, not the company's. The company if left to its own devices would run the stock to 300.00 per share and THEN issue a few million new shares in a secondary. READ and LEARN!!. This stock ran to 7.00 on great news recently and then the idiot daytraders shorted it back down. Without their messing this thing up, we would be seeing the true value of this companies promise represented in its shareprice. Truth be told; it's only a matter of time before that awareness expands to the institutions and brokerages out there and we see shareprices scream into the double digits and quite possibly into the triple digits within the next 36 months. The CANF Pipeline of clinical trials validate an entire biotechnological approach that has far reaching consequences on multiple fronts. Hang on to your shares. These low volume days are relatively meaningless. There are more 10 million share days on the horizon just on the other side of 2016